ViroGates announces the outcome of its rights issue

15.12.2023 10:58:37 CET | ViroGates | Changes in share capital and votes

COMPANY ANNOUNCEMENT - No. 22-2023 - 15 December 2023

MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA OR JAPANOR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

BIRKERØD, DENMARK – ViroGates A/S (“ViroGates or the “Company”), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces the outcome of its rights issue of shares of up to approximately DKK 15.1 million, for which the subscription period ended 13 December 2023. Shares corresponding to approximately 92% of the issue were subscribed for, and ViroGates thus raises approximately DKK 13.9 million before deduction of costs related to the issue.

Outcome

The “Maximum Offer” was comprised of 3,350,507 shares. The outcome of the rights issue of shares shows that 2,559,722 shares, corresponding to approximately 76% of the Maximum Offer, have been subscribed by the exercise of subscription rights (incl. subscription undertakings). In addition, 537,325 shares, corresponding to approximately 16% of the Maximum Offer, were subscribed for without subscription rights. Through the issue, ViroGates raises approximately DKK 13.9 million before deduction of costs related to the issue.

Notification regarding allocation

Allocation of shares has been made according to the principles described in company announcement no. 17, published on 9 November 2023. Subscribers who are allocated shares subscribed for without subscription rights will receive an allocation notice in the form of a settlement note. Payment for such shares is to be made according to the instructions on the settlement note, typically handled via the depository bank.

Number of shares and share capital

When the rights issue has been registered with the Danish Business Authority, the total number of shares in ViroGates A/S will amount to 6,447,554 shares, and the share capital amount to DKK 6,447,554.

Indicative use of proceeds

The proceeds from the rights issue will be used as described in company announcement no. 17 from 9 November 2023. The proceeds will be used on the initiatives to promote new application areas and continue reimbursement processes in Europe, obtain marketing approval and initiate expansion to the US, and to approach the health clinics and longevity segment.

Advisers

Västra Hamnen Corporate Finance acts as financial advisor, Mazanti-Andersen acts as legal advisor, and Danske Bank acts as the issuing agent and settlement agent in the rights issue.

The announcement can be found at https://www.virogates.com/investor/announcements

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. [phone], email: [e-mail]

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. [phone], email: [e-mail]

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs, and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Forward-looking statements

Certain information set forth and given in this announcement contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates’ business, projects and joint ventures; (iii) execution of ViroGates’ vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates’ projects; (v) completion of ViroGates’ projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates’ current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this announcement are based upon what management of ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, [phone], [e-mail]

Attachments

• 20231215 -ViroGates Company ann. 22 - outcome of rights issue.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases